Share on LinkedInShare on LinkedIn

ARTICLE · 14 OCTOBER 2025

Belgian Competition Authority Issues Guidance On Information Exchange Between Pharmaceutical Companies For Combination Therapies

A&O Shearman
A&O Shearman
Contributor

A&O Shearman

Introducing A&O Shearman Unparalleled global depth for a changing world. Today more than ever,...

View firm profile
Explore more from A&O Shearman

On 10 September 2025, the Belgian Competition Authority (the BCA) published a communication clarifying the conditions under which pharmaceutical companies may exchange information...

BelgiumAntitrust/Competition Law

On 10 September 2025, the Belgian Competition Authority (the BCA) published a communication clarifying the conditions under which pharmaceutical companies may exchange information specifically in the context of reimbursement applications for combination therapies in Belgium. This guidance responds to a request from the National Institute for Health and Disability Insurance (the NIHDI), which is contemplating to introduce a dedicated reimbursement procedure for combination therapies. The BCA's communication aims to facilitate access to innovative treatments for patients, while ensuring compliance with competition law.

Background

Combination therapies involve the use of two or more distinct medicines, often developed by different pharmaceutical companies. They typically pair a foundational or "backbone" medicine, already authorised and reimbursed as a monotherapy for a specific therapeutic indication, with an "add-on" product, developed either for use as a

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See more popular content from